VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Consensus Rating of “Reduce” by Brokerages

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have been given an average rating of “Reduce” by the five research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $0.95.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 3rd.

VistaGen Therapeutics Stock Performance

Shares of VistaGen Therapeutics stock opened at $0.30 on Thursday. The firm has a market cap of $13.18 million, a PE ratio of -0.16 and a beta of 0.41. The business’s 50 day simple moving average is $0.42 and its 200 day simple moving average is $0.53. VistaGen Therapeutics has a 52-week low of $0.20 and a 52-week high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings results on Monday, June 15th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). VistaGen Therapeutics had a negative return on equity of 133.02% and a negative net margin of 5,487.01%.The firm had revenue of $0.47 million for the quarter, compared to analyst estimates of $0.40 million. During the same period last year, the company earned ($1.67) EPS. As a group, equities research analysts predict that VistaGen Therapeutics will post -1.32 EPS for the current year.

Institutional Trading of VistaGen Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of VTGN. Cubist Systematic Strategies LLC acquired a new stake in VistaGen Therapeutics during the 1st quarter valued at $25,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of VistaGen Therapeutics in the third quarter valued at $39,000. Boothbay Fund Management LLC raised its position in shares of VistaGen Therapeutics by 10.8% in the third quarter. Boothbay Fund Management LLC now owns 197,024 shares of the company’s stock valued at $699,000 after purchasing an additional 19,166 shares during the period. Bank of America Corp DE raised its position in shares of VistaGen Therapeutics by 1,068.0% in the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after purchasing an additional 19,331 shares during the period. Finally, Millennium Management LLC bought a new position in shares of VistaGen Therapeutics in the third quarter valued at about $73,000. Institutional investors and hedge funds own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.